Cove D H, Woods K L, Smith S C, Burnett D, Leonard J, Grieve R J, Howell A
Br J Cancer. 1979 Nov;40(5):710-8. doi: 10.1038/bjc.1979.251.
The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.
对8种潜在肿瘤标志物在69例Ⅰ期和Ⅱ期乳腺癌患者以及57例Ⅲ期和Ⅳ期患者中的临床应用价值进行了评估。局部乳腺癌患者中13%血清癌胚抗原（CEA）浓度升高，晚期乳腺癌患者中这一比例为65%。在有肿瘤进展或消退临床证据的患者中，83%的病例血清CEA水平有相应变化。采用其中4种标志物（癌胚抗原（CEA）、乳白蛋白、α亚基和触珠蛋白），局部疾病患者中33%一种或多种标志物血清浓度升高，晚期乳腺癌患者中这一比例为81%。然而，标志物浓度通常仅略有升高，不太可能为肿瘤负荷提供敏感的指导。原发性乳腺癌提取物中分别有68%、43%和40%可检测到CEA、乳白蛋白和α亚基。
